European Committee for Treatment & Research in Multiple Sclerosis

Startseite
Schweiz
Basel
European Committee for Treatment & Research in Multiple Sclerosis

The European Committee for Treatment & Research in Multiple Sclerosis - the world's largest organisat

SAVE THE DATE: MSMilan2023, the 9th joint ECTRIMS-ACTRIMS meeting, will be held as a hybrid event on 11–13 October in Milan, Italy

23/12/2025

🔎 ECTRIMS Research Spotlight — Top 3 Spotlights of 2025

With 16,000+ reads in 2025, ECTRIMS Spotlights remain a go-to resource for staying up to date with key advances in MS research.

To mark the end of the year, we’re highlighting our top three articles in a weekly countdown.

2️⃣ Spotlight of the Year — Applying the Proposed 2024 McDonald Criteria: Global Clinical Perspectives

Read it here ➡️ https://ectrims.eu/insights/applying-the-proposed-2024-mcdonald-criteria-global-clinical-perspectives/

Delays in diagnosing MS persist—even within the very systems designed to prevent them. Limited resources remain a major contributor to diagnostic delays across many countries, but they are not the only factor. Notably, nearly half of World Bank high- and upper-middle-income countries reported at least one barrier to adopting the 2017 McDonald Criteria. This underscores the need to accompany the 2024 revisions with enhanced dissemination and education efforts.

Written by our scientific content writer Stefania de Vito, the article features interviews with Sasitorn Siritho - Mahidol University - and Ethel Ciampi - Pontificia Universidad Católica de Chile.

This Spotlight takes its place as the second highlight in our year-end Top 3 series, continuing our weekly journey through the year’s most-read features.

20/12/2025

📢 Applications are now open for the ECTRIMS Summer School 2026!

The 11th ECTRIMS Summer School on Statistical Techniques & Tools in MS Research will be held in Naples, Italy, from 8 to 10 June 2026.

📝 Apply now via myECTRIMS 👉 https://my.ectrims.eu/school/summer
⏰ Application deadline: 19 January 2026, 23:59 CET

The programme is designed for early-career clinicians, researchers, and data scientists interested in applying statistical methods to MS research.

It provides a solid foundation in standard statistical techniques and tools, combining a theoretical component – covering core statistical concepts and study design – with a practical component focused on the application of statistical methods to MS datasets.

19/12/2025

🎙️ This week, we’re excited to share the third most-listened episode of The ECTRIMS Podcast in 2025…

Episode 3️⃣ of the Year: Day One Highlights of ECTRIMS 2025

🍏 Apple: https://lnkd.in/eEu23mgU
🎧 Spotify: https://lnkd.in/euTDFm9T

On 24 September, the opening day of ECTRIMS 2025, Professor Maria Pia Amato from Università degli Studi di Firenze and host Brett Drummond discussed the most relevant highlights from day one of .

ECTRIMS 2025 delivered a full series of daily highlight episodes covering key insights at the 41st ECTRIMS Congress and 30th RiMS - Rehabilitation in Multiple Sclerosis Conference. Explore them all here ▶️ https://ectrims.eu/podcast/

MStranslate

18/12/2025

🔎ECTRIMS Research Spotlight — Top 3 Spotlights of 2025

With over 16,000 reads this year, our “MS Research Spotlight” series is strengthening its role as a key resource for staying informed and inspired by the latest advances in MS research.

To close out the year, we’re featuring a weekly countdown of our top three articles.

3️⃣ Spotlight of the Year — Why MS Strikes Unevenly: The Epidemiological Clues

Read it here ➡️ https://ectrims.eu/insights/why-ms-strikes-unevenly-the-epidemiological-clues/

The Spotlight explores epidemiological research that helps explain why MS affects populations unevenly. It highlights recent findings from large-scale national registries and genetic studies, showing how a range of risk factors—from genetics to socioeconomic determinants—shape our understanding of this complex condition.

Written by our scientific content writer Stefania de Vito, the article features interviews with Melinda Magyari of Rigshospitalet & Københavns Universitet - University of Copenhagen and Eva Strijbis of Amsterdam UMC Run, who shed light on the evolving landscape of MS epidemiology.

This piece also opens our year-end Top 3 series—follow along as we reveal a new featured Spotlight each week.

17/12/2025

🌍 Patient Community Day 2025 — the impact, by the numbers.

This year's PCD marked our most global and inclusive Patient Community Day yet.

📊 PCD 2025 at a glance:
• 3,537 registrations
• 2,383 attendees — an 85% increase from 2024
• 89 countries represented
• 500+ questions and comments from the global community
• 40+ Supporting Partners across 17 countries
• 95% of participants found the event relevant and valuable

From breakthrough science to lived experience, Patient Community Day continues to connect people living with MS, NMOSD, and MOGAD with the research, experts, and insights shaping the future of treatment and care.

🌍 Explore our Impact Report 2025:
https://www.ectrimspatientcommunity.eu/impact-report/

16/12/2025

🔬 CAR T cells: An Exciting Research Path Worth Pursuing

Read our new MS research here: https://ectrims.eu/insights/car-t-cell-therapy-an-exciting-research-path-worth-pursuing/

Researchers are exploring new target antigens to expand CAR T-cell therapy beyond cancer to autoimmune diseases. Because CAR T cells can better pe*****te tissues and cross the blood–brain barrier compared with many conventional therapies, they represent a promising potential treatment for MS.

Professor Amit Bar-Or from the University of Pennsylvania tells us, “It is an exciting and growing field, with multiple types of engineered cells now being explored. Immune cells are taken out of the body, genetically modified outside the body, and then transfused back."

Professor Manuel Friese of Universität Hamburg says, "There are several advantages. First, CAR T cells persist in the body for a longer period and can eliminate B cells across multiple compartments. Unlike antibodies, which primarily target circulating B cells in the blood, CAR T cells are living drugs that can migrate throughout the body."

15/12/2025

| Beyond the Congress

The Best of Slide Decks brings you top-rated abstracts on clinical aspects, therapy, pathology and pathogenesis, imaging & biomarkers, and RiMS - Rehabilitation in Multiple Sclerosis.

📥 Download the slides on myECTRIMS and spread the science with your colleagues and peers this festive season ➡️ https://my.ectrims.eu/bestofslidedecks

13/12/2025

🎙️ As we continue our year-end countdown of the Top 5 most-listened episodes of the ECTRIMS Podcast, we’re excited to share the No. 4 spot...

Episode 4️⃣ of the Year: 2024 Revisions of the McDonald Diagnostic Criteria: What Neurologists Need to Know.

🍏 Apple: https://apple.co/4mu3doT
🎧 Spotify: https://bit.ly/4nbMcB3

In early September, the 2024 revisions of the McDonald Diagnostic Criteria for MS were published in The Lancet Neurology. In this episode, Xavier Montalban, former Chair of the International Advisory Committee on Clinical Trials in MS, and Jiwon Oh of the University of Toronto joined host Brett Drummond to discuss how the updated criteria may expedite diagnosis, reduce misdiagnosis, and shape the future of MS care globally.

Stay tuned — the No. 3 episode of the year drops next week!

MStranslate | CEMCAT (Centre d'Esclerosi Múltiple de Catalunya) |

12/12/2025

🎥 Rewatch one of the most inspiring moments from !

Since 1969, the MS Charcot Award has honored individuals whose lifetime of outstanding research has transformed our understanding and treatment of multiple sclerosis.

This year, the 2025 Charcot Award celebrates Prof. Ludwig Kappos — a visionary leader whose decades of groundbreaking work have helped redefine MS diagnosis, treatment, and patient care worldwide.

From leading the MS Clinical Group at the Max Planck Society early in his career to shaping global research at the Universität Basel, Prof. Kappos has been instrumental in developing nearly every approved MS therapy over the past three decades. His contributions have revolutionised care, bringing safer, more effective, and more personalised treatment options to people living with MS.

🌟 Charcot Lecture: Developing MS Therapeutics – Success Factors and Call for Innovation

Key themes included:
• Clinical trials as a driver of therapeutic progress in MS
• Current and future challenges in MS care
• Emerging innovations for trials and daily practice

▶️ Watch the lecture replay: https://ectrims-congress.virtual-meeting.org/programme/session/67944

11/12/2025

🎙️ “None of the tests that we use in the BICAMS, the MACFIMS, the Rao's Brief Repeatable Battery were designed expressly for MS… we need to kind of reset and say, let's create new measurement tools to take us to the next frontier.” Vicky Leavitt from Columbia University

Cognitive symptoms in MS are common—but not always captured well by current tools. In our latest podcast, Vicky Leavitt and Tom Fuchs from Amsterdam UMC talk about the state of cognition research, if measurement still lags behind clinical need, and how new tools may change the field forever.

🎧 Listen now:
Spotify: https://bit.ly/48vMjm7
Apple: https://apple.co/4oMh8HY

The episode covers:
• Why cognition changes matter for treatment decisions
• How to interpret meaningful decline
• Why patients often describe “I can’t get the words out”
• New digital approaches, including language & memory tests

The ECTRIMS Podcast is hosted by Brett Drummond from MStranslate.

10/12/2025

Our December 2025 Newsletter is out now!

Read it here 👉https://ectrims.eu/december-2025-newsletter/

Catch up on this year’s key milestones — from a highly successful ECTRIMS Congress, to the growing impact of Patient Community Day, to the newly revised 2024 McDonald criteria. We also highlight our recent educational activities.

07/12/2025

🏥 Don't miss our Clinical Case NeuroWebinar tomorrow!

This session will focus on the multifactorial decision-making process involved in choosing the optimal treatments for individuals with NMOSD.

Our expert panel from the Ludwig-Maximilians-Universität München will present a compelling clinical case, then delve into the risks and benefits of NMOSD therapy. They will also highlight the reasons and challenges behind switching NMOSD treatments — from disease activity and infections to older age and comorbidities.

Gain valuable insights from leading experts and deepen your understanding of the key factors shaping NMOSD treatment decisions.

🗓️Tuesday, 9 December
🕕 18:00 - 19:00 CET

Register for FREE via myECTRIMS: https://my.ectrims.eu/webinars/111

Adresse

Reinacherstrasse 131
Basel
4053

Telefon

+41616867777

Webseite

http://www.ectrims.eu/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von European Committee for Treatment & Research in Multiple Sclerosis erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.